A comprehensive view of U.S. Food and Drug Administration (FDA). This page highlights a small sample of our full coverage.
For real-time access, please log in to your Consumer Wellness Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Gilead resubmits application to FDA for approval of long-acting injectable HIV drug lenacapavir after FDA refused authorization in February due to drug’s compatibility with borosilicate glass vial; Gilead now using aluminosilicate glass vial for drug
Published: June 29, 2022 by SeeNews Pharmaceuticals
Commentary: FDA banning Juul e-cigarettes in US market creates US$1B opportunity for other brands, as vape sector generates about US$7B in annual sales; Juul estimated to have 33% market share, and Cowen notes 'there's a lot of market share for grabs'
Published: June 28, 2022 by Forbes
FDA approves Cybin’s New Drug Application for clinical trial evaluating oral CYB003 deuterated psilocybin analog to treat major depressive disorder; drug is first novel psilocybin analog to start clinical development, with Phase1/2a trial starting soon
Published: June 28, 2022 by Business Wire
Celgene’s US$6.4B lawsuit against Bristol Myers Squibb over contingent payouts for three therapies can continue US district court rules; Celgene shareholders allege Bristol Myers did not make sufficient effort to have drugs approved by FDA
Published: June 28, 2022 by SeeNews Pharmaceuticals
FDA clears Bristol Myers Squibb’s Breyanzi lisocabtagene maraleucel cell therapy to treat large B-cell lymphoma in patients not eligible for stem cell transplant; drug uses genetically modified immune cells that fight cancer
Published: June 28, 2022 by SeeNews Pharmaceuticals

Ask us about our Consumer Wellness market view

Trending Chart

Interactive chart with headline count